Case Report Journal of Cardiovascular Medicine publishes imaging in Cardiovascular Medicine, case reports in Cardiovascular Medicine, videos in Cardiovascular Medicine case reports journal etc. This is further assessment and peer-reviewed by the editors of Cardiovascular Medicine Journal. It publishes Cardiovascular Case Reports, Clinical Images of Cardiology, Clinical Studies of Cardiac medicines, Clinical and Experimental Studies, Cardiovascular Medicine Research, Case Series, Original Research Articles. Focusing on the medicine Anticoagulants, Antiplatelet Agents, Angiotensin-Converting Enzyme (ACE), Angiotensin II Receptor Blockers, Beta Blockers, Alpha Blockers, Calcium Channel Blockers, Diuretics and Vasodilators etc.

Case Report Journal of Cardiovascular Medicine is an Editorial Tracking Based System for quality in review process for accepting original research and review articles from across the world. Review processing is performed by the editorial board members of Case Report Journal of Cardiovascular Medicine or outside experts; at least two independent reviewers approval followed by editor approval is required for acceptance of any citable manuscript. Authors may submit manuscripts and track their progress through the system, hopefully to publication. Reviewers can download manuscripts and submit their opinions to the editor. Editors can manage the whole Submission, Review, Peer review, Revise, Publish process.

Anticoagulants Case Reports Journal
Anticoagulants, commonly known as blood thinners, are chemical substances that prevent or reduce coagulation of blood, prolonging the clotting time. Anticoagulants are a family of medications that stop your blood from clotting too easily. They can break down existing clots or prevent clots from forming in the first place.

Antiplatelet Agents Case Reports Journal
Antiplatelet are medicines that prevent blood clots from forming. Read about the different types of antiplatelets, how they work, and their side effects. Over time, numerous antiplatelet agents have been developed with a multitude of indications.

Angiotensin-Converting Enzyme in Case Reports Journal
Angiotensin-converting enzyme, or ACE, is a central component of the renin–angiotensin system, which controls blood pressure by regulating the volume of fluids in the body. It converts the hormone angiotensin I to the active vasoconstrictor angiotensin II. Angiotensin-converting enzyme (ACE) inhibitors are medications that help relax the veins and arteries to lower blood pressure.

Beta Blockers Case Reports Journal
Beta blockers, also spelled ?-blockers and also as beta-adrenergic blocking agents are a class of medications that are predominantly used to manage abnormal heart rhythms, and to protect the heart from a second heart attack after a first heart attack.

Case Reports Journal of Alpha Blockers
Alpha-blockers, also known as alpha-blockers or alpha-adrenoreceptor antagonists, are a class of pharmacological agents that act as antagonists on alpha-adrenergic receptors. Alpha blockers are a type of blood pressure medication.

Calcium Channel Blockers in Case Reports Journal
Calcium channel blockers are a type of medication that people take to increase the flow of blood and oxygen to the heart. Calcium is necessary for muscle contractions to occur throughout the body. This mineral enters muscle cells through ion channels, which are tiny pores on the surface of the cell.

Diuretics Case Report Journal
A diuretic is any substance that promotes diuresis, the increased production of urine. This includes forced diuresis. A diuretic tablet is sometimes colloquially called a water tablet.

Vasodilators Case Reports Journal
Vasodilators are medications that open blood vessels. They affect the muscles in the walls of the arteries and veins, preventing the muscles from tightening and the walls from narrowing.

Manuscript Submission
Authors may submit their manuscripts through the journal's online submission portal:
https://www.cardiologycasereportsjournal.org/journal/Case-Report-Journal-of-Cardiovascular-Medicine.html

(or) Send an e-mail attachment to the Editorial Office E-mail Id:
[email protected]